Improvements in Acute, Subacute Low Back Pain Seen Within First Six Weeks
22 Jan 2024
Clinical Result
MONDAY, Jan. 22, 2024 -- Patients with acute and subacute low back pain experience considerable improvements in pain and disability within the first six weeks, according to a review published online Jan. 22 in CMAJ, the journal of the Canadian Medical Association.
Sarah B. Wallwork, Ph.D., from IIMPACT in Health in Adelaide, Australia, and colleagues updated a 2012 systematic review and meta-analysis to improve understanding of the clinical course of acute, subacute, and persistent low back pain. Data were included from 95 studies, with 60 separate cohorts (17,974 participants) in the systematic review and 47 cohorts (9,224 participants) in the meta-analysis.
The researchers found that with inception time uncorrected (i.e., time since study entry), the estimated mean pain score was 56 at baseline, 26 at six weeks, 22 at 26 weeks, and 21 at 52 weeks for the acute pain cohort (moderate-certainty evidence); 63, 29, 29, and 31, respectively, for the subacute pain cohort (moderate-certainty evidence); and 56, 48, 43, and 40, respectively, for the persistent pain cohort (very low-certainty evidence). Compared with the clinical course of pain, the clinical course of disability was slightly more favorable.
"Most people with acute and subacute low back pain begin to improve within the first six weeks, but many have ongoing pain and disability," the authors write. "Identifying and escalating care among people with subacute low back pain who are recovering slowly seems a critical focus of intervention."
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.